Ted Monohon's most recent trade in Quince Therapeutics Inc was a trade of 1,871 Common Stock done at an average price of $1.0 . Disclosure was reported to the exchange on March 6, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 06 Mar 2023 | 1,871 | 27,440 (0%) | 0% | 1.0 | 1,834 | Common Stock |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.72 per share. | 05 Dec 2022 | 1,640 | 29,311 (0%) | 0% | 0.7 | 1,181 | Common Stock |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.64 per share. | 06 Sep 2022 | 1,520 | 30,951 (0%) | 0% | 1.6 | 2,493 | Common Stock |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 06 Jun 2022 | 1,529 | 32,471 (0%) | 0% | 3.1 | 4,770 | Common Stock |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 34,000 | 34,000 (0%) | 0% | 0 | Common Stock | |
| Quince Therapeutics Inc | Ted Monohon | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 20,000 | 20,000 | - | - | Employee Stock Option (right to buy) |